C12N 2760/10071
Demonstrated in vivo effect
C12N2760/10071 (Demonstrated in vivo effect) appears on 2 US grants and 5 published applications in this corpus.
Search patents in C12N- Granted patents
- 2
- Published applications
- 5
- Assignees
- 4
- Inventors
- 11
- Latest grant
- 29 Oct 2024
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2020 | 0 | 2 |
| 2021 | 0 | 0 |
| 2022 | 0 | 1 |
| 2023 | 0 | 0 |
| 2024 | 2 | 0 |
| 2025 | 0 | 2 |
By publication year.
Recent patents
- Multivalent mopevac-based immunogenic composition for vaccination against new world arenaviruses and therapeutic use(s) thereof3 Jul 2025US 2025/0213670 A1
- Method for producing an antitumoral arenavirus as well as arenavirus mutants17 Apr 2025US 2025/0122244 A1Abalos Therapeutics GmbH
- Method for producing an antitumoral arenavirus as well as arenavirus mutants3 Feb 2022US 2022/0033445 A1Abalos Therapeutics GmbH
- Lassa vaccine1 Oct 2020US 2020/0308555 A1Centre National De La Recherche Scientifique
- Compositions and Methods for Generating an Immune Response to LASV4 Jun 2020US 2020/0171141 A1GeoVax, Inc.
Most cited
By later US patents